Immune checkpoint inhibitor-related myasthenia gravis, myositis and myocarditis: a triad but not at the same time?
Authors:
Open Access
- 16 January 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 117 (5) , 373-374
Abstract
Immune checkpoint inhibitor-related myasthenia gravis and its overlap syndrome with myocarditis and myositis occur early after initiation of therapy and are associated with significant mortality. 1, 2 The clinical course of immune checkpoint inhibitor-mediated myasthenia gravis tends to be more aggressive than its de novo counterparts and management strategies must be adapted to recognize this. We describe a presentation of this condition, which may offer further insights into its disease course and management.Keywords
This publication has 4 references indexed in Scilit:
- Improved outcomes with early immunosuppression in patients with immune-checkpoint inhibitor induced myasthenia gravis, myocarditis and myositis: a case seriesSupportive Care in Cancer, 2023
- Emergency presentations in patients treated with immune checkpoint inhibitorsEuropean Journal of Cancer, 2020
- Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literatureJournal for ImmunoTherapy of Cancer, 2019
- Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance studyJournal for ImmunoTherapy of Cancer, 2019